Cancer and Metastasis Reviews

, Volume 33, Issue 2–3, pp 619–628

Bone-targeting agents in prostate cancer

  • Daniel L. Suzman
  • Sosipatros A. Boikos
  • Michael A. Carducci
Article

DOI: 10.1007/s10555-013-9480-2

Cite this article as:
Suzman, D.L., Boikos, S.A. & Carducci, M.A. Cancer Metastasis Rev (2014) 33: 619. doi:10.1007/s10555-013-9480-2

Abstract

Bone metastases are present in the vast majority of men with advanced prostate cancer, representing the main cause for morbidity and mortality. Recurrent or metastatic disease is managed initially with androgen deprivation but the majority of the patients eventually will progress to castration-resistant prostate cancer, with patients developing bone metastases in most of the cases. Survival and growth of the metastatic prostate cancer cells is dependent on a complex microenvironment (onco-niche) that includes the osteoblasts, the osteoclasts, the endothelium, and the stroma. This review summarizes agents that target the pathways involved in this complex interaction between prostate cancer and bone microenvironment and aim to transform lethal metastatic prostate cancer into a chronic disease.

Keyword

Bone-targeting agents Prostate cancer Bone metastases 

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Daniel L. Suzman
    • 1
  • Sosipatros A. Boikos
    • 1
  • Michael A. Carducci
    • 1
  1. 1.Prostate Cancer Research ProgramSidney Kimmel Comprehensive Cancer Center at Johns HopkinsBaltimoreUSA

Personalised recommendations